Detalhes bibliográficos
| Resumo: | Antimicrobial resistance is on the rise globally, prompting increased research and development (R&D) of phage therapy as a strategy to address difficult-to-treat bacterial infections. We review the current state of phage therapy research, including major operational, epistemic, and biological challenges for phage R&D, and discuss some new approaches to developing the technology motivated by recent breakthroughs such as artificial intelligence and synthetic phage production. In addition, we contextualize these R&D challenges and opportunities in light of the ongoing predicament of commercial antimicrobial innovation and current publicprivate efforts to reinvigorate the pipeline of antimicrobial drug discovery. We conclude with reflections on the potential for new phage therapies to be readily accessible across all income contexts to better ensure broad patient access, and consider possible alternatives to current public and publicprivate solutions for phage therapy and production. |
|---|
| Autores principais: | Turner, Paul E. |
|---|
| Outros Autores: | Azeredo, Joana; Buurman, Ed. T.; Green, Sabrina; Haaber, Jakob Krause; Haggstrom, Douglas; Carvalho, Koichi Kameda de Figueiredo; Kirchhelle, Claas; Moreno, Mercedes Gonzalez; Pirnay, Jean-Paul; Portillo, Mirza Alas |
|---|
| Assunto: | antimicrobial resistance biofilm biotechnology patient access personalized medicine |
|---|
| Ano: | 2024 |
|---|
| País: | Portugal |
|---|
| Tipo de documento: | artigo |
|---|
| Tipo de acesso: | acesso aberto |
|---|
| Instituição associada: | Universidade do Minho |
|---|
| Idioma: | inglês |
|---|
| Origem: | RepositóriUM - Universidade do Minho |
|---|